NU6102, CDK1/cyclin B and CDK2/cyclin A3 inhibitor (ab144317)

Overview

  • Product name

    NU6102, CDK1/cyclin B and CDK2/cyclin A3 inhibitor
  • Description

    Potent CDK1/cyclin B and CDK2/cyclin A3 inhibitor. Antiproliferative agent.
  • Biological description

    Potent CDK1/cyclin B and CDK2/cyclin A3 inhibitor (IC50 values are 9.5 and 5.4 nM for CDK1/cyclin B and CDK2/cyclin A3 respectively). Antiproliferative agent. Inhibits CDK4/D1, DYRK1A, PDK1 ROCKII (IC50 values are 1.6, 0.9, 0.8 and 0.6 μM respectively). Induces G2/M cell cycle arrest. Shows antitumor effects in vivo.
  • Purity

    > 98%
  • CAS Number

    444722-95-6
  • Chemical structure

    Chemical Structure

Properties

  • Chemical name

    4-[[6-(Cyclohexylmethoxy)-7H-purin-2-yl]amino]benzenesulfonamide
  • Molecular weight

    402.47
  • Molecular formula

    C18H22N6O3S
  • PubChem identifier

    4566
  • Storage instructions

    Store at -20°C. Store In the Dark. Store under desiccating conditions. This product is air and light sensitive and impurities can occur as a result of air oxidation or due to metabolism by microbes.
  • Solubility overview

    Soluble in DMSO to 50 mM
  • Handling

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.

  • SMILES

    C1CCC(CC1)COC2=NC(=NC3=C2NC=N3)NC4=CC=C(C=C4)S(=O)(=O)N
  • Source

    Synthetic

  • Research areas

References

This product has been referenced in:

  • Thomas HD  et al. Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301. Eur J Cancer 47:2052-9 (2011). Read more (PubMed: 21570822) »
  • Johnson N  et al. Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells. Br J Cancer 102:342-50 (2010). Read more (PubMed: 20010939) »
  • Davies TG  et al. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nat Struct Biol 9:745-9 (2002). Read more (PubMed: 12244298) »

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab144317.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES, NOT FOR USE IN HUMANS"
For licensing inquiries, please contact partnerships@abcam.com

Sign up